PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19997078-4 2010 Moreover, pretreatment of DCs with the PPAR-gamma agonist pioglitazone reverted these effects of Ang II on DCs via suppression of the MAPK and NF-kappaB signaling pathways at least in part. Pioglitazone 58-70 nuclear factor kappa B subunit 1 Homo sapiens 143-152 26024533-7 2015 In human chondrocytes, AGEs could induce cytosol IkappaBalpha degradation and increase the level of nuclear NF-kappaB p65, which was inhibited by PPARgamma agonist pioglitazone. Pioglitazone 164-176 nuclear factor kappa B subunit 1 Homo sapiens 108-117 21808640-10 2011 Pioglitazone very rapidly down-regulated the activated state of peripheral monocytes/macrophages as assessed by mRNA expression of NFkappaB and NFkappaB-modulated cytokines and decreased plasma levels of cardiovascular risk marker proteins independent of glycemic control. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 131-139 21808640-10 2011 Pioglitazone very rapidly down-regulated the activated state of peripheral monocytes/macrophages as assessed by mRNA expression of NFkappaB and NFkappaB-modulated cytokines and decreased plasma levels of cardiovascular risk marker proteins independent of glycemic control. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 144-152 17846974-1 2007 Thiazolidinediones such as pioglitazone have been shown to exert anti-inflammatory effects independent of their insulin sensitizing effects by reducing activation of the proinflammatory transcription factor NF-kappaB in animal models of experimental diabetes. Pioglitazone 27-39 nuclear factor kappa B subunit 1 Homo sapiens 207-216 15472206-8 2004 Pioglitazone and sodium salicylate thus protect human islets against the detrimental effects of IL-1beta and high glucose by blocking NFkappaB activation and may therefore be useful in retarding the manifestation and progression of diabetes. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 134-142 15550788-8 2004 Pretreatment of cardiac fibroblasts with pioglitazone (10 M) reduced all these effects of A-R. Further, A-R stimulated intracellular reactive oxygen species (ROS) generation and activated the redox-sensitive transcription factor NF-kappaB (both P < 0.05). Pioglitazone 41-53 nuclear factor kappa B subunit 1 Homo sapiens 229-238 15550788-11 2004 Inhibition of ROS generation and induction of NF-kappaB in cardiac fibroblasts during A-R may be a mechanism of action of pioglitazone. Pioglitazone 122-134 nuclear factor kappa B subunit 1 Homo sapiens 46-55 15466667-13 2004 The effects of pioglitazone are mediated by the modulation of ROS release and redox-sensitive transcription factor NF-kappaB. Pioglitazone 15-27 nuclear factor kappa B subunit 1 Homo sapiens 115-124 15472206-2 2004 The aim of this study was to determine whether two drugs believed to block NFkappaB activation, the thiazolidinedione (glitazone) pioglitazone and the nonsteroidal antiinflammatory drug sodium salicylate, can protect human beta-cells against the toxic effects of IL-1beta and high glucose in vitro. Pioglitazone 130-142 nuclear factor kappa B subunit 1 Homo sapiens 75-83 12667961-9 2003 The NF-kappaB activation caused by CRP was inhibited by 15-deoxy-12,14-prostaglandin J2 and the PPARgamma activators, rosiglitazone and pioglitazone. Pioglitazone 136-148 nuclear factor kappa B subunit 1 Homo sapiens 4-13 30224430-5 2018 This suppression of TNFalpha expression by pioglitazone was mainly mediated by transrepression of nuclear factor-kappaB (NF-kappaB) DNA-binding activity. Pioglitazone 43-55 nuclear factor kappa B subunit 1 Homo sapiens 121-130 32215295-9 2020 The obtained results revealed that: 1) increased expression of IL-6, NO and Caspase-3 in serum and cerebrospinal fluid in patients after TBI, and decreased PPARgamma in brain tissue; 2) pioglitazone could improve neurobehavioral and reduce brain edema in rats after TBI; 3) the protective effect of pioglitazone was achieved by activating PPARgamma and reducing NF-kappaB and IL-6. Pioglitazone 186-198 nuclear factor kappa B subunit 1 Homo sapiens 362-371 32215295-10 2020 The neuroprotective effect of pioglitazone on TBI was mediated through the PPARgamma/NF-kappaB/IL-6 pathway. Pioglitazone 30-42 nuclear factor kappa B subunit 1 Homo sapiens 85-94 32655263-8 2020 A number of synthetic molecules have been found to suppress NO expression either dependent on the NF-kappaB signaling pathway (i.e., dexamethasone, pioglitazone, tropisetron) or independent from this pathway (i.e., nicotine, prednisolone, celecoxib, beta-adrenoceptor antagonists). Pioglitazone 148-160 nuclear factor kappa B subunit 1 Homo sapiens 98-107 32215295-0 2020 Pioglitazone ameliorates neuronal damage after traumatic brain injury via the PPARgamma/NF-kappaB/IL-6 signaling pathway. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 88-97 26673543-0 2016 The peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents NF-kappaB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway. Pioglitazone 61-73 nuclear factor kappa B subunit 1 Homo sapiens 83-92 27515513-0 2016 Pioglitazone inhibits advanced glycation end product-induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-kappaB. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 143-152 26673543-9 2016 These results suggest that the PPAR-gamma agonist pioglitazone prevents NF-kappaB activation in cisplatin nephrotoxicity through a reduction in p65 acetylation via the AMPK-SIRT1/p300 pathway. Pioglitazone 50-62 nuclear factor kappa B subunit 1 Homo sapiens 72-81 30096396-0 2018 Pioglitazone inhibits advanced glycation induced protein modifications and down-regulates expression of RAGE and NF-kappaB in renal cells. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 113-122 30096396-7 2018 Pioglitazone has potentially restored cellular antioxidants and reduced levels of IL-6 and TNF-alpha by declining expression of membrane RAGE and NF-kappaB. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 146-155 27133446-0 2017 Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-kappaB inflammation signals. Pioglitazone 0-12 nuclear factor kappa B subunit 1 Homo sapiens 77-86 27133446-5 2017 The effect of pioglitazone on nuclear factor-kappa B (NF-kappaB)-dependent reporter gene transcription induced by LPS was analyzed by NF-kappaB-luciferase assay. Pioglitazone 14-26 nuclear factor kappa B subunit 1 Homo sapiens 30-52 27133446-5 2017 The effect of pioglitazone on nuclear factor-kappa B (NF-kappaB)-dependent reporter gene transcription induced by LPS was analyzed by NF-kappaB-luciferase assay. Pioglitazone 14-26 nuclear factor kappa B subunit 1 Homo sapiens 54-63 27133446-5 2017 The effect of pioglitazone on nuclear factor-kappa B (NF-kappaB)-dependent reporter gene transcription induced by LPS was analyzed by NF-kappaB-luciferase assay. Pioglitazone 14-26 nuclear factor kappa B subunit 1 Homo sapiens 134-143 27133446-8 2017 Molecular biology analysis found that pioglitazone could affect the apoptosis and inflammation related signal via modulating the activity of NF-kappaB signal. Pioglitazone 38-50 nuclear factor kappa B subunit 1 Homo sapiens 141-150 27133446-10 2017 CONCLUSIONS: Our results suggested that pioglitazone demonstrated antitumor activity against the human retinoblastoma Y79 cells by inhibiting cell growth, inducing apoptosis and modulating NF-kappaB pathway, and thus delayed tumor growth in vivo. Pioglitazone 40-52 nuclear factor kappa B subunit 1 Homo sapiens 189-198 27973395-7 2016 In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFkappaB. Pioglitazone 64-67 nuclear factor kappa B subunit 1 Homo sapiens 144-152 27515513-7 2016 AGEs-induced degradation of IkappaBalpha and translocation of nuclear NF-kappaB p65 is reversed by pioglitazone. Pioglitazone 99-111 nuclear factor kappa B subunit 1 Homo sapiens 70-79 27515513-10 2016 These findings suggest that pioglitazone, a PPARgamma agonist, inhibits AGEs-induced chondrocytes apoptosis and degeneration via suppressing the activation of MAPK and NF-kappaB. Pioglitazone 28-40 nuclear factor kappa B subunit 1 Homo sapiens 168-177 26673543-4 2016 The results showed that the PPAR-gamma agonist pioglitazone decreased the expression of NF-kappaB p65 transcription target genes (e.g., IL-6, IL-1beta, and TNF-alpha) and inhibited histological injury and inflammatory cells infiltration in cisplatin nephrotoxicity. Pioglitazone 47-59 nuclear factor kappa B subunit 1 Homo sapiens 88-97 26673543-5 2016 The suppression of NF-kappaB activity following pioglitazone treatment inhibited the cisplatin-induced IkappaB-alpha degredation and NF-kappaB p65 subunit translocation. Pioglitazone 48-60 nuclear factor kappa B subunit 1 Homo sapiens 19-28 26673543-5 2016 The suppression of NF-kappaB activity following pioglitazone treatment inhibited the cisplatin-induced IkappaB-alpha degredation and NF-kappaB p65 subunit translocation. Pioglitazone 48-60 nuclear factor kappa B subunit 1 Homo sapiens 133-142 26072064-8 2015 Dual treatment of pioglitazone and eplerenone demonstrated synergistic effect on reducing ICAM-1 and IL-6 expression and alleviating NF-kappaB activation when compared with their monotherapies in TNF-alpha activated renal tubular cells. Pioglitazone 18-30 nuclear factor kappa B subunit 1 Homo sapiens 133-142 26072064-10 2015 CONCLUSIONS: Our data suggest that pioglitazone, in a PPAR-gamma-dependent manner, trans-represses MR signaling by suppressing NF-kappaB activation. Pioglitazone 35-47 nuclear factor kappa B subunit 1 Homo sapiens 127-136